• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 20, 2020

View Archived Issues
DNA in test tubes

Precision cookie crumbles right; hard drive against DMD sited in potential $2.5B-plus Lilly deal

Precision Biosciences Inc. CEO Matthew Kane said the company is in “active discussions around additional partnerships in vivo and in other areas across our organization,” after scoring a deal with Eli Lilly and Co. centered on the firm’s Arcus genome-editing platform. “There’s no conceivable way in the near term that we’re going to advance all of the possibilities of Arcus on our own,” he said. Read More
Scientist injecting vaccine into Earth

Confidence in ‘spectacular’ COVID-19 vaccine trial wins resonant among experts

In a world more familiar with the 30% to 70% efficacy rates of seasonal flu vaccines, news of 95% efficacy rates for two of the major late-stage COVID-19 vaccines in development seems thrilling. But do such robust-sounding numbers, the product of relatively early analyses, really merit the enthusiasm they’ve garnered? Read More
respiratory-lung-COVID-19-coronavirus.png

Mesoblast licenses remestemcel-L to Novartis in deal worth up to $1.3B

PERTH, Australia – Mesoblast Ltd. inked an exclusive global licensing deal with Novartis AG for the development, manufacture and commercialization of Mesoblast’s mesenchymal stromal cell product remestemcel-L, with an initial focus on the acute respiratory distress syndrome, including that associated with COVID-19, just six weeks after the FDA issued a complete response letter for the therapy as a treatment for steroid-refractory acute graft-versus-host disease. Read More

One step at a time: FDA issues EUA for Lilly’s COVID-19 therapy

In what the FDA calls “an incremental step” in treating hospitalized COVID-19 patients, the agency has issued an emergency use authorization (EUA) for Eli Lilly and Co.’s baricitinib in combination with remdesivir. Read More
Remdesivir vial and syringe

WHO recommends against use of Gilead's Veklury for COVID-19

Citing a lack of evidence that it improves survival, the need for ventilation or time to clinical improvement, the World Health Organization (WHO) has advised doctors against using Gilead Sciences Inc.’s antiviral Veklury (remdesivir) to treat COVID-19. Read More
Globe and currency symbols

Biopharma deals have almost reached the summit

Still not there yet, but close. Biopharma projected deal values are currently at $159.4 billion, just shy of the 2019 record of $160.3 billion. With about six weeks left in the year, it is highly likely that 2020 will come out on top. Read More
George Chen, co-founder, chairman and CEO, D3 Bio

D3 Bio launches with a hefty $200M series A financing

HONG KONG – D3 Bio Inc. is the new kid on the biopharma block in Shanghai, kicking off with a $200 million series A financing backed by some of Asia’s most prominent venture capital firms. Read More

Former Mimedx CEO, COO convicted on fraud, conspiracy charges

The latest global regulatory news, changes and updates affecting biopharma. Read More

Appointments and advancements for Nov. 20, 2020

New hires and promotions in the biopharma industry, including: AC Immune, Humacyte, Swanbio, Tarsus. Read More

Financings for Nov. 20, 2020

Biopharmas raising money in public or private financings, including: Avrobio, Oragenics, Stealth, Stoke. Read More

In the clinic for Nov. 20, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amarin, Clear Creek, Glycostem, Inovio, Marinomed, Redhill. Read More

Other news to note for Nov. 20, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aptevo, Black Diamond, Coimmune, F-star, GSK, Immunomic, Mannkind, Matinas, Metavant, Metuchen, Neurotrope, Petros, Poxel, Sosei, Spring Bank, Sumitomo, United, Vectura. Read More

Regulatory actions for Nov. 20, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ADC, Alexion, Amgen, Astrazeneca, Beigene, Biontech, Eli Lilly, Gilead, Immupharma, Pfizer. Read More

Money raised by biopharma: 2020 vs. 2019

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019. Read More

Biopharma money raised: Jan. 1-Nov. 19, 2020

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Biggest gainers and losers for the week of Nov. 16-20, 2020

The top 10 biopharma stock gainers and losers for the week. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 25, 2025.
  • Martin Kulldorf, ACIP chair

    No vote, ACIP recurring theme at CDC confirmation hearing

    BioWorld
    Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Hands holding gears

    Kymera brings on Gilead as partner while Sanofi alters deal

    BioWorld
    Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another. Kymera and Gilead Sciences...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe